Form 4: Sarepta Director Sells Shares for Tax Obligations

Sarepta Therapeutics Director Stephen Mayo sold 7,239 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Summary

• Stephen Mayo, a Director at Sarepta Therapeutics, Inc. (SRPT), sold 7,239 shares of common stock.
• The transaction occurred on March 12, 2026, at a price of $17.02 per share.
• The sale was conducted to generate cash for the payment of taxes resulting from the vesting of certain restricted stock unit awards.
• Following this transaction, Mayo beneficially owns 1,765 shares of Sarepta Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for insiders covering tax liabilities upon RSU vesting, and not a reflection of company performance or future prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales for tax purposes related to restricted stock unit (RSU) vesting are common and generally not indicative of a change in management's outlook on the company's future performance, but rather a personal financial planning event.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of insider ownership, but is a routine event for tax purposes and unlikely to significantly impact shareholder sentiment.

Key Dates

Recommendation

The transaction is a routine insider sale for tax purposes following RSU vesting and does not provide new fundamental information to warrant a change in investment recommendation. Investors should hold and monitor company-specific developments.

Keywords

Sarepta Therapeutics, SRPT, Stephen Mayo, Insider Trading, Form 4, Stock Sale, Director, Restricted Stock Units, Tax Obligations